Thelansis

Familial Mediterranean Fever (FMF) Market Outlook Thelansis’s “Familial Mediterranean Fever (FMF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Familial Mediterranean Fever (FMF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest ...

Familial Mediterranean Fever (FMF) Market Outlook Thelansis’s “Familial Mediterranean Fever (FMF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Familial Mediterranean Fever (FMF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Familial Mediterranean Fever (FMF) Overview Familial Mediterranean Fever (FMF) is an autoinflammatory genetic disorder characterized by recurring fevers and inflammation in the abdomen, lungs, and joints, causing severe pain. Symptoms may include a rash or headache. The onset of symptoms usually occurs in childhood and before the age of 20 years, with attacks manifesting within 2 to 4 hours and lasting ...

 Familial Mediterranean Fever (FMF) is an autoinflammatory genetic disorder characterized by recurring fevers and inflammation in the abdomen, lungs, and joints, causing severe pain. Symptoms may include a rash or headache. The onset of symptoms usually occurs in childhood and before the age of 20 years, with attacks manifesting within 2 to 4 hours and lasting 6 hours to 4 days. Mutations cause FMF in the MEFV gene on chromosome 16p13.3. Over 300 MEFV mutations have been identified, with 70 to 80% of cases attributed to V726A, M680I, E148Q, M694V, and M694I mutations. Pyrin plays a role in the pathophysiology of FMF, as it is found in the cytoskeleton of circulation cells, including white blood cells, which play a role in the immune response to pathogens. Mutations in the MEFV gene disrupt pyrin and its function, activating the inflammatory pathway through IL-1beta. Treatment for FMF involves using colchicine to prevent attacks, normalize inflammation, and prevent the development o...